Swiss earnings calls, October 2026: Galderma and Schindler raise 2026 guidance
Galderma said it raised its 2026 net sales growth guidance to 22.5%–23.5% at constant currency, from 19%–21%. Schindler raised its 2026 margin guidance for earnings before interest and taxes to 13.5% from 13%.
An update from FactIQ, written from company statements in earnings calls of companies listed in Switzerland. What is FactIQ?
Key figures
- Galderma, net sales growth guidance, fiscal year 2026, at constant currency
- 22.5%–23.5%stated by the chief financial officer; raised from 19%–21%
- Schindler, margin guidance for earnings before interest and taxes, fiscal year 2026
- 13.5%stated by the chief executive and the chief financial officer; raised from 13%
- Roche, divarasip peak-sales potential
- CHF 2.2 billion to CHF 3 billionstated by the chief executive; increased following Crexendo 1 data
- Nestlé, organic growth outlook, fiscal year 2026
- 3% to 4%stated by the chief financial officer
Galderma and Schindler raised parts of their guidance for fiscal year 2026
- Galderma: The chief financial officer said the company raised its fiscal year 2026 net sales growth outlook to 22.5%–23.5% at constant currency, from 19%–21%. The company confirmed its core EBITDA (earnings before interest, taxes, depreciation and amortisation) margin guidance of approximately 26% at constant currency. The chief financial officer said the company expects injectable aesthetics growth of 12%–13% at constant currency in fiscal year 2026. The chief financial officer also said Galderma plans to communicate extended midterm guidance in early 2027.
- Schindler: The chief executive said revenue grew 5% in local currencies in the third quarter of fiscal year 2026. The company maintained its guidance for low to mid single digit revenue growth. It raised its EBIT (earnings before interest and taxes) margin guidance to 13.5% from 13%. The chief financial officer cited efficiency savings, cost-inflation mitigation and a slight expected mix tailwind. The company reduced its restructuring-cost expectation to up to USD 40 million from up to USD 60 million.
Roche reiterated its group guidance and raised outlooks for some medicines
The chief executive said Roche reiterated fiscal year 2026 guidance for mid-single-digit sales growth and high-single-digit core EPS (earnings per share) growth. Roche expects to increase dividends further. The chief executive said the Hemlibra growth outlook was upgraded from mid-single-digit to high-single-digit growth. Roche increased divarasip's peak-sales potential to CHF 2.2 billion to CHF 3 billion. An executive said Roche now projects Kadcyla sales a few hundred million lower than previously expected because of increased competitive pressure.
Nestlé kept its outlook for fiscal year 2026
The chief financial officer said Nestlé expects organic growth of 3% to 4%, with RIG (real internal growth) accelerating versus 2025. Nestlé expects free cash flow to be above CHF 9 billion, unchanged from prior guidance. The chief financial officer said currency is expected to be a headwind of around 2% to full-year 2026 sales growth, assuming current spot rates. The chief financial officer also said the North America business will face a tough year-over-year comparison in the fourth quarter of fiscal year 2026.
Source: Earnings calls of companies listed in Switzerland. See which companies FactIQ covers.
About FactIQ and these updates
- What FactIQ is. FactIQ is a database of official statistics from government agencies, central banks and international organisations in the US, China, India, Europe and elsewhere. AI assistants such as Claude and ChatGPT connect to it to look up the exact figures and cite the agency that published them. It also holds what companies report in their filings and say on their earnings calls.
- How an update is made. FactIQ reads each new earnings call or filing and stores the statements with numbers, each with the exact quote it came from. An AI model then writes a short summary of those statements. Before it is published, code checks that every number in the summary matches a stored statement, and a second review checks that nothing is overstated or presented as fact when the company only expects it.
- What this is not. The figures are what each company said or filed. FactIQ does not rate companies or recommend shares.